Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Issues Quarterly Earnings Results

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) announced its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, FiscalAI reports.

Oaktree Acquisition Corp. III Life Sciences Price Performance

Shares of OACC traded down $0.03 during midday trading on Friday, reaching $10.77. 595 shares of the stock were exchanged, compared to its average volume of 29,429. Oaktree Acquisition Corp. III Life Sciences has a 52 week low of $10.30 and a 52 week high of $10.88. The company’s 50 day moving average is $10.71 and its two-hundred day moving average is $10.68.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

A number of hedge funds have recently added to or reduced their stakes in OACC. Rangeley Capital LLC increased its position in Oaktree Acquisition Corp. III Life Sciences by 52.8% during the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after purchasing an additional 21,156 shares during the period. DLD Asset Management LP lifted its position in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% in the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares during the period. Lineage Point Capital LP purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the 4th quarter worth approximately $2,461,000. Empyrean Capital Partners LP boosted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 20.0% during the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Radcliffe Capital Management L.P. boosted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 67.1% during the fourth quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock valued at $3,989,000 after purchasing an additional 151,403 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences currently has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.